NASDAQ · APLM
Apollomics, Inc.
$20.80+$0.83 (+4.16%)
Apollomics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 26.48% below the high.
Loading market information…
NASDAQ · FEMY · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Femasys Inc.’s quoted price sits in the lower half of its reported 52-week range, 93.9% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Femasys Inc.’s next earnings report is currently expected on Nov 17, 2026, with estimated earnings per share of -$0.47. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Femasys Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Femasys Inc., a biomedical company established in 2004 and based in Suwanee, Georgia, primarily targets the women's healthcare market within the United States. The firm's innovative product line includes permanent contraceptive solutions such as FemBloc and FemChec, alongside FemaSeed, which is an artificial insemination offering. For diagnostic purposes, Femasys provides FemCerv, a biopsy device utilized for endocervical curettage, and FemEMB, a product candidate intended for endometrial sampling to assist in the detection of uterine cancer. Additionally, the company markets its FemVue saline-air device across various international regions, including the U.S., Europe, Canada, and Japan. Its infertility-related products are supplied to obstetrician-gynecologists, other allied healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. The company also offers a range of non-surgical product technologies.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:09 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 |
|---|
| May 8, 2025 |
| -$4.60-35.29% vs estimate |
| $341.26K-70.13% vs estimate |
| Q4 2024 | Mar 27, 2025 | -$4.60-24.32% vs estimate | $582.11K-65.01% vs estimate |
|---|
| Q3 2024 | Nov 12, 2024 | -$4.80-20.0% vs estimate | $554.91K-18.05% vs estimate |
|---|
THE ANALYST VIEW
6 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$20.80+$0.83 (+4.16%)
Apollomics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 26.48% below the high.
$6.50-$0.16 (-2.4%)
Envoy Medical, Inc.’s quoted price sits in the lower half of its reported 52-week range, 31.87% below the high.
$8.80+$0.38 (+4.51%)
Harvard Bioscience, Inc.’s quoted price sits in the upper half of its reported 52-week range, 6.38% below the high.
$15.90-$1.74 (-9.86%)
Ekso Bionics Holdings, Inc.’s quoted price sits in the upper half of its reported 52-week range, 40.14% below the high.
$3.31-$0.19 (-5.43%)
BriaCell Therapeutics Corp.’s quoted price sits in the lower half of its reported 52-week range, 75.35% below the high.
$0.68+$0.00 (+0.22%)
Dare Bioscience, Inc.’s quoted price sits in the lower half of its reported 52-week range, 81.97% below the high.
$0.73-$0.08 (-10.09%)
Ainos, Inc.’s quoted price sits in the lower half of its reported 52-week range, 81.21% below the high.
$1.89+$0.04 (+2.16%)
Processa Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 81.56% below the high.
